DifGen Pharmaceuticals, a manufacturer of generic pharmaceuticals, announced it has received approval from the US Food and Drug Administration (FDA) for its fluorometholone ophthalmic suspension, 0.1%,  a complex generic formulation used to treat eye inflammation.

Fluorometholone ophthalmic suspension is a corticosteroid indicated for treating steroid-responsive inflammatory conditions of the eye's anterior segment.

This is the second generic FDA approval of this complex suspension product. The first was introduced by Amneal Pharmaceuticals in 2024.